These findings suggested that the expression level of ABCG2 could serve as one of the biomarkers for predicting sensitivity to the SN-38/erlotinib combination in cancer cells that are SLFN11 positive and inherently responsive to SN-38. The gene discussed is ABCG2; the disease is cancer.